Assess whether the primary endpoint will survive FDA scrutiny (cd7589)

SITUATION The working file is RWE protocol that may not meet regulator expectations after a CMO 483 that maps to the NDA CMC module. Clinical-development physician in a biologics company planning a biosimilar pathway has to name Proceed under protocol or Pause the pathway for this Pharma & Life Sciences Clinical and Evidence Strategy file.

DECISION Clinical-development physician in a biologics company planning a biosimilar pathway must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using RWE protocol that may not meet regulator expectations after a CMO 483 that maps to the NDA CMC module.

HYPOTHESES TO TEST 1. A CMO 483 that maps to the NDA CMC module is noise around an already-controlled Clinical and Evidence Strategy process in a biologics company planning a biosimilar pathway, given RWE protocol that may not meet regulator expectations. 2. A CMO 483 that maps to the NDA CMC module is the event in RWE protocol that may not meet regulator expectations that forces Proceed under protocol for clinical-development physician under Pharma & Life Sciences. 3. RWE protocol that may not meet regulator expectations shows a one-file miss after a CMO 483 that maps to the NDA CMC module, not a Clinical and Evidence Strategy program failure. 4. RWE protocol that may not meet regulator expectations cannot decide the primary endpoint will yet after a CMO 483 that maps to the NDA CMC module; hold is the only Pharma & Life Sciences close a biologics company planning a biosimilar pathway can defend.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on the primary endpoint will. 2. Check whether RWE protocol that may not meet regulator expectations supports the labeled claim clinical-development physician would keep. 3. Map FDA-response timing and owner in a biologics company planning a biosimilar pathway. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read RWE protocol that may not meet regulator expectations against a CMO 483 that maps to the NDA CMC module and write the one fact that would move the primary endpoint will for clinical-development physician.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (RWE protocol that may not meet regulator expectations after a CMO 483 that maps to the NDA CMC module). Lead with the Pharma & Life Sciences option RWE protocol that may not meet regulator expectations can support after a CMO 483 that maps to the NDA CMC module, then the two facts that force it, then the Monday action for clinical-development physician in a biologics company planning a biosimilar pathway.